Viroclinics Biosciences Receives Majority Investment from Gilde Healthcare Services

viroclinicsViroclinics Biosciences, a Rotterdam, the Netherlands-based virology contract research organization, received a majority investment from Gilde Healthcare Services.

The amount of the deal was not disclosed.

Founded in 2001 as a spin-off from the virology department at the Erasmus Medical Centre in Rotterdam, the Netherlands, and led by Bob van Gemen, CEO, Viroclinics Biosciences BV is a virology contract research organization, serving the biopharmaceutical community as a pre-clinical and clinical reference laboratory for supporting the development of new chemical entities, vaccines and antiviral compounds targeting viral infectious diseases.

At the start of 2013, it opened a samples processing facility in Boston USA.

With the transaction, the founding institute Erasmus University Medical Center (Erasmus MC) exited the company. Viroclinics intends now to use the proceeds to expand service its offering and plans to continue its collaboration with the Viroscience lab of Erasmus MC and co-develop new laboratory services in the field of virology.



Join the discussion